RENAISSANCE GROUP LLC - Astellas Pharma Inc ownership

Astellas Pharma Inc's ticker is ALPMY and the CUSIP is 04623U102. A total of 9 filers reported holding Astellas Pharma Inc in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
RENAISSANCE GROUP LLC ownership history of Astellas Pharma Inc
ValueSharesWeighting
Q3 2023$5,438,880
-12.7%
391,745
-6.5%
0.25%
-7.8%
Q2 2023$6,229,766
+3.6%
418,988
-1.4%
0.27%
-2.5%
Q1 2023$6,010,452
-7.7%
424,827
-0.8%
0.28%
-13.5%
Q4 2022$6,509,955
+8.8%
428,467
-5.0%
0.32%
-0.9%
Q3 2022$5,983,000
-17.8%
450,940
-3.5%
0.32%
-14.1%
Q2 2022$7,275,000
-4.5%
467,299
-3.4%
0.38%
+9.3%
Q1 2022$7,616,000
-0.2%
483,681
+3.0%
0.34%
+10.6%
Q4 2021$7,628,000
-14.2%
469,618
-12.7%
0.31%
-19.3%
Q3 2021$8,888,000
-11.9%
538,188
-7.0%
0.38%
-9.0%
Q2 2021$10,083,000
+7.3%
578,502
-5.2%
0.42%
+6.3%
Q1 2021$9,399,000
-1.1%
610,206
-0.9%
0.40%
-2.9%
Q4 2020$9,505,000
+8.1%
615,651
+4.0%
0.41%
+0.7%
Q3 2020$8,790,000
-20.7%
591,985
-10.9%
0.41%
-23.1%
Q2 2020$11,078,000
-4.0%
664,125
-10.9%
0.53%
-17.8%
Q1 2020$11,544,000
-21.1%
745,784
-12.3%
0.64%
+6.6%
Q4 2019$14,638,000
+13.3%
850,714
-6.2%
0.60%
+10.3%
Q3 2019$12,917,000
-7.1%
907,339
-7.1%
0.55%
-3.2%
Q2 2019$13,910,000
-7.8%
976,349
-3.0%
0.56%
-6.3%
Q1 2019$15,080,000
+44.8%
1,006,415
+23.4%
0.60%
+25.9%
Q4 2018$10,416,000
-41.8%
815,443
-20.6%
0.48%
-23.8%
Q3 2018$17,910,0001,026,3610.63%
Other shareholders
Astellas Pharma Inc shareholders Q1 2022
NameSharesValueWeighting ↓
RENAISSANCE GROUP LLC 469,618$7,628,0000.31%
TODD ASSET MANAGEMENT LLC 193,500$3,148,0000.07%
SCOUT INVESTMENTS, INC. 225,247$3,665,0000.05%
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY 193,500$3,148,0000.03%
SILVERCREST ASSET MANAGEMENT GROUP LLC 113,135$1,838,0000.01%
Private Capital Group, LLC 924$15,0000.00%
PNC FINANCIAL SERVICES GROUP, INC. 35$1,0000.00%
IFP Advisors, Inc 40$1,0000.00%
First Horizon Advisors, Inc. 120$1,0000.00%
CAPTRUST FINANCIAL ADVISORS 3,790$62,0000.00%
View complete list of Astellas Pharma Inc shareholders